Ask AI
Back Back
Individualizing CLL SLL Therapy

CE / CME

Expert Perspectives on Updates and Advances in Individualizing CLL/SLL Therapy Across the Disease Course

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Registered Nurses: 1.50 Nursing contact hour

Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 19, 2025

Expiration: December 18, 2025

Danielle M. Brander
Danielle M. Brander, MD
Brad Kahl
Brad Kahl, MD
Sameer A. Parikh
Sameer A. Parikh, MBBS
CME/CE Information

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
Continue to Activity
1.

Patient Case 1: 63-Yr-Old Man With Newly Diagnosed CLL



  • A 63-yr-old man was diagnosed with CLL




    • del (17p)/TP53 wild type

    • IGHV mutation



  • The patient has a past medical history of hypertension and diabetes

  • The patient needs to initiate therapy because of symptoms and cytopenias

  • He desires a fixed-duration, all-oral regimen because of his career as a truck driver

Which of the following would you recommend as the best first-line therapy for this patient?

2.

Patient Case 2: A 76-Yr-Old Woman With Previously Untreated CLL



  • 76-yr-old woman was diagnosed with CLL in 2023

    • Rai stage 1, IGHV unmutated, FISH reveals del(17p)

    • Patient has a long-standing history of hypertension controlled with 3 medicines, coronary artery disease controlled medically, atrial fibrillation which was controlled, and baseline creatinine of 1.8

    • Initially, patient was followed with watchful waiting but developed PD in 2024

    • Workup revealed Hb of 9.9, white blood cell count of 77, and platelet of 90K

    • CT scan revealed bulky axillary nodes of 7 cm bilateral and retroperitoneal nodes of 9 cm

    • Patient has difficulty with mobility due to arthritis and lives 3 hr from the treatment center

    • She is worried about travel requirements and wants to start treatment that gives her the best outcome



Which of the following would you recommend as the best first-line therapy for this patient?

3.

Patient Case: An 86-Yr-Old Man With Relapsed CLL



  • An 86-yr-old man was diagnosed with CLL in 2013 and has experienced multiple relapses

    • Initially diagnosed as Rai stage 1, IGHV unmutated, FISH reveals trisomy 12



  • He has received bendamustine + rituximab in 2014, followed by venetoclax + rituximab from 2016 to 2018, and acalabrutinib in 2019

  • He has remained on acalabrutinib but recently developed worsening lymphocytosis and rapidly enlarging lymph nodes, consistent with progressing CLL but without clinical or laboratory signs of Richter transformation

  • NGS revealed acquired BTK C481S mutation

  • He states that he would prefer another oral therapy in his next line of treatment

Which of the following would you recommend as the best next-line therapy for this 86-yr-old patient?

4.

Patient Case: A 72-Yr-Old Woman With CLL



  • A 72-yr-old woman was initially treated for CLL with bendamustine + rituximab, resulting in a 7-yr remission

  • She then develops symptomatic progression and is treated with venetoclax + rituximab for 2 yr, resulting in a 2-yr remission

  • She again requires treatment due to progressive lymphocytosis, cytopenia, and fatigue and receives zanubrutinib

  • She tolerates treatment well but experiences disease progression 3 yr later, after which she receives pirtobrutinib

  • The patient experiences symptomatic disease progression 9 mo later

Which of the following would you recommend as the next best therapy for this patient with CLL and multiple relapses?

5.

How confident are you in your ability to identify patients with CLL/SLL who may be eligible to enroll in a clinical trial?

Continue to Activity